These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

94 related articles for article (PubMed ID: 3396151)

  • 1. Comparative in vitro cytotoxicities of adriamycin (ADM) and 4'[(9-acridinyl)-amino] methane sulphon-m-anisidide (mAMSA).
    Hill BT; Whelan RD
    Cancer Chemother Pharmacol; 1988; 22(1):90-1. PubMed ID: 3396151
    [No Abstract]   [Full Text] [Related]  

  • 2. A comparison of adriamycin and mAMSA. II. Studies with V79 and human tumour multicellular spheroids.
    West CM; Stratford IJ
    Cancer Chemother Pharmacol; 1987; 20(2):109-14. PubMed ID: 2822273
    [TBL] [Abstract][Full Text] [Related]  

  • 3. A reassessment of the mechanism of action of 4'-[(9-acridinyl)-amino]methanesulphon-m-anisidide.
    Marshall B; Ralph RK
    Eur J Cancer Clin Oncol; 1982 Jun; 18(6):553-7. PubMed ID: 6811280
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Blocked 5'-termini in the fragments of chromosomal DNA produced in cells exposed to the antitumor drug 4'-[(9-acridinyl)-amino]methanesulphon-m-anisidide (mAMSA).
    Marshall B; Ralph RK; Hancock R
    Nucleic Acids Res; 1983 Jun; 11(12):4251-6. PubMed ID: 6306581
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The action of the DNA intercalating agents 4'-(9-acridinylamino) methanesulphon-m-anisidide and 1,4-bis(butylamino) benzo[g]phthalazine in U-937 human promonocytic cells: relationship between cell cycle and differentiation.
    Pérez C; Campayo L; Navarro P; García-Bermejo L; Aller P
    Biochem Pharmacol; 1994 Jul; 48(1):75-82. PubMed ID: 7519013
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Reduced DNA break formation and cytotoxicity of the topoisomerase II drug 4'-(9'-acridinylamino)methanesulfon-m-anisidide when combined with hyperthermia in human and rodent cell lines.
    Kampinga HH; van den Kruk G; Konings AW
    Cancer Res; 1989 Apr; 49(7):1712-7. PubMed ID: 2538233
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Evaluation of an amsacrine analog in a human tumor cloning system.
    Lathan B; Von Hoff DD; Clark GM; Elslager EE
    Cancer Chemother Pharmacol; 1989; 24(4):230-2. PubMed ID: 2752503
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Camptothecin, teniposide, or 4'-(9-acridinylamino)-3-methanesulfon-m-anisidide, but not mitoxantrone or doxorubicin, induces degradation of nuclear DNA in the S phase of HL-60 cells.
    Del Bino G; Darzynkiewicz Z
    Cancer Res; 1991 Feb; 51(4):1165-9. PubMed ID: 1997159
    [TBL] [Abstract][Full Text] [Related]  

  • 9. On the mechanism of action of 4'-[(9-acridinyl)-amino] methanesulphon-m-anisidide.
    Ralph RK
    Eur J Cancer (1965); 1980 May; 16(5):595-600. PubMed ID: 6771143
    [No Abstract]   [Full Text] [Related]  

  • 10. Cytotoxic action and cell cycle effects of ALGA, a peptidic derivative of the antileukemic drug amsacrine.
    Collyn-d'Hooghe M; Bernier JL; Henichart JP
    Cancer Biochem Biophys; 1987 Sep; 9(3):257-64. PubMed ID: 3435897
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Cellular responses to methyl-N-[4-9-acridinylamino)-2-methoxyphenyl] carbamate hydrochloride, an analogue of amsacrine active against non-proliferating cells.
    Moreland N; Finlay GJ; Dragunow M; Holdaway KM; Baguley BC
    Eur J Cancer; 1997 Sep; 33(10):1668-76. PubMed ID: 9389932
    [TBL] [Abstract][Full Text] [Related]  

  • 12. A carbamate analogue of amsacrine with activity against non-cycling cells stimulates topoisomerase II cleavage at DNA sites distinct from those of amsacrine.
    Baguley BC; Leteurtre F; Riou JF; Finlay GJ; Pommier Y
    Eur J Cancer; 1997 Feb; 33(2):272-9. PubMed ID: 9135499
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [Establishment of the multidrug-resistant cell line K562/A02 and its drug-resistant properties].
    Luan FJ
    Zhonghua Zhong Liu Za Zhi; 1993 Mar; 15(2):101-3. PubMed ID: 7900978
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Altered topoisomerase IIalpha and multidrug resistance-associated protein levels during drug selection: adaptations to increasing drug pressure.
    Matsumoto Y; Takano H; Nagao S; Fojo T
    Jpn J Cancer Res; 2001 Sep; 92(9):968-74. PubMed ID: 11572765
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Involvement of DNA topoisomerase II in the selective resistance of a mammalian cell mutant to DNA minor groove ligands: ligand-induced DNA-protein crosslinking and responses to topoisomerase poisons.
    Smith PJ; Bell SM; Dee A; Sykes H
    Carcinogenesis; 1990 Apr; 11(4):659-65. PubMed ID: 2157558
    [TBL] [Abstract][Full Text] [Related]  

  • 16. A human small cell lung carcinoma cell line, resistant to 4'-(9-acridinylamino)-methanesulfon-m-anisidide and cross-resistant to camptothecin with a high level of topoisomerase I.
    Prost S; Riou G
    Biochem Pharmacol; 1994 Aug; 48(5):975-84. PubMed ID: 8093110
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Evidence that mAMSA induces topoisomerase action.
    Marshall B; Darkin S; Ralph RK
    FEBS Lett; 1983 Sep; 161(1):75-8. PubMed ID: 6309576
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Correlation between experimentally and clinically demonstrated activity of two new cytotoxic agents in breast cancer.
    Bailey MJ; Smith IE
    Anticancer Res; 1985; 5(4):419-22. PubMed ID: 3839994
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Cytokinetic resistance of Lewis lung carcinoma to cyclophosphamide and the amsacrine derivative CI-921.
    Baguley BC; Finlay GJ; Wilson WR
    Prog Clin Biol Res; 1986; 223():47-61. PubMed ID: 3809201
    [No Abstract]   [Full Text] [Related]  

  • 20. Two independent amsacrine-resistant human myeloid leukemia cell lines share an identical point mutation in the 170 kDa form of human topoisomerase II.
    Lee MS; Wang JC; Beran M
    J Mol Biol; 1992 Feb; 223(4):837-43. PubMed ID: 1311390
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.